FarmaMondo is proud to sponsor this unique event, Early Access Programmes Conference, held in London , UK, on 29th - 30 th November 2016. The only event dealing with the planning and execution of Early Access and managed access programmes. Key Challenges and Topics of debate include: 1. Anticipating Demand and Deciding...

Following the successful experience of last year’s participation FarmaMondo will return to exhibit at EXPOPHARM 2016 which will be held in Munich, Germany from October 12 to October 16, 2016. FarmaMondo team will be pleased to host you in our stand J27 – Hall C4 and discuss business opportunities...

Farmamondo and AOP Orphan signs an exclusive registration, marketing and distribution agreement for AOP’s novel therapy Tetrabenazine indicated for Huntington disease. The agreement covers the territory of Russian federation and is valid for 5 years with relevant milestones. Farmamondo’s local affiliate will be responsible to achieve Marketing Authorization and commercially...

FarmaMondo approves Normokineztine in Russian Federation for Huntington disease patients. The product, license to FarmaMondo from AOP Orphan, has been approved as the sole indicated therapy currently available for Russian patients suffering from the indicated disease. FarmaMondo will launch the product in H1 2016 through...

FarmaMondo announces the approval of Ellanse, an innovative product in the esthetic segment, by the Taiwan local regulatory body – TFDA – as a medical device class II. The product was licensed to FarmaMondo on an exclusive basis for certain markets and has been approved as...

FarmaMondo SA announces it has established operations in Argentina to allow direct to hospital supply of unlicensed medicines, to cover spontaneous needs and in support of the company’s portfolio of Managed Access Programs. The Argentinian team will cover all local activities to support physicians and other stakeholders looking to fulfill...